The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
 
Yoshiki Arakawa
Speakers' Bureau - Abbvie; Brainlab; Carl Zeiss Meditec; Chugai Pharma; CSL Behring; Daiichi Sankyo; Eisai; Integra LifeSciences; Meiji Seika Kaisha; Merck; Nippon Kayaku; Novocure; Otsuka; UCB
Research Funding - Astellas Pharma; Brainlab; Chugai Pharma; CSL Behring; Daiichi Sankyo; Eisai; Meiji Seika Kaisha; Merck; Mitsubishi Tanabe Pharma; Nihon Medi-Physics; Pfizer; Philips, Inc.; Sanofi; Siemens; Stryker; Takeda; ZEISS
 
Yoshiko Okita
No Relationships to Disclose
 
Yoshitaka Narita
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Novocure; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Sumitomo Group
Research Funding - Bayer; Daiichi Sankyo; Eisai; Ono Pharmaceutical; Stella pharma; Sumitomo Group